Advertisement


Nabil F. Saba, MD, on Preventing Radiation-Induced Mucositis in Patients With Squamous Cell Carcinoma of the Head and Neck

2024 Multidisciplinary Head and Neck Cancers Symposium

Advertisement

Nabil F. Saba, MD, of Emory University, discusses phase II study results suggesting parenteral administration of TK-90 may be an effective strategy for preventing radiation-induced oral mucositis in patients with squamous cell carcinoma of the head and neck (Abstract 10).



Related Videos

Head and Neck Cancer

Nabil F. Saba, MD, on Head and Neck Cancer: Long-Term Survival Findings With Pembrolizumab and Cabozantinib

Nabil F. Saba, MD, of Emory University, discusses study findings on 2-year survival rates in patients with recurrent metastatic head and neck squamous cell carcinoma who received pembrolizumab plus cabozantinib. The progression-free survival rate of 32% and the overall survival rate of 55% suggest a durable clinical activity of this combination therapy (Abstract 2).

Head and Neck Cancer

Pooja Karukonda, MD, on Coping With Financial Toxicity in Head and Neck Cancer

Pooja Karukonda, MD, of Duke University Medical Center, discusses findings from the PaRTNer study, which addressed the large financial burden faced by patients with head and neck cancer undergoing radiotherapy, particularly older, non-White, female, and low-income patients. Dr. Karukonda discusses some ways to counter this adverse effect (Abstract 13).

Head and Neck Cancer
Skin Cancer

Christopher A. Barker, MD, on New Data on Vismodegib and Radiotherapy for Basal Cell Carcinoma of the Head and Neck

Christopher A. Barker, MD, of Memorial Sloan Kettering Cancer Center, discusses phase II study results showing that patients with locally advanced, unresectable basal cell carcinoma of the head and neck experienced improved quality of life after induction and concurrent vismodegib with curative-intent radiation treatment. According to Dr. Barker, the data on this strategy may provide a beneficial benchmark for clinical practice (Abstract 9).

Head and Neck Cancer

Samuel Regan, MD, and Benjamin Rosen, PhD, on De-escalating Radiotherapy for HPV-Related Oropharyngeal Cancer

Samuel Regan, MD, and Benjamin Rosen, PhD, both of the University of Michigan, discuss results from a phase II trial showing the possibility of de-escalating chemoradiation treatment for patients with HPV-related oropharyngeal cancer, based on an FDG-PET imaging biomarker. The data suggest that patients may experience few locoregional recurrences and less toxicity (Abstract 16).

Head and Neck Cancer

Evan M. Graboyes, MD, MPH, on Decreasing Delays in Adjuvant Therapy for Head and Neck Cancer

Evan M. Graboyes, MD, MPH, of the Medical University of South Carolina, discusses the results of the NDURE study, which explored the delays in starting postoperative radiation therapy in patients with head and neck cancer and ways to improve the timeliness and equity of treatment. Delays in this therapy are associated with higher recurrence and poorer survival in this population (Abstract LBA2).

Advertisement

Advertisement




Advertisement